ID: MRFR/HC/6249-CR | March 2019 | Region: Global | 150 pages
The oral Anticoagulants Market is expected to reach USD 22,561.24 Million by 2023 with a growth rate of CAGR of 12.50%. Oral anticoagulant is a drug that is used to prevent blood clotting by adding a few amounts of oral anticoagulant into the blood. Anticoagulant represses the synthesis and several clotting functions that are present in the blood. The anticoagulant drug is used to prevent the blood from clotting inside the arteries or veins or any other amplification of blood clot which is circulating in the bloodstream.
Oral anticoagulants which are also known as blood thinners are widely used by doctors to decrease or reduce the coagulant of the blood during the blood clotting period. There are a number of medical conditions where the blood clotting risk is relatively high, such conditions include deep vein thrombosis, atrial fabrication, myocardial infarction, stroke, pulmonary embolism, and others. There was a massive growth in the global anticoagulant industry during the forecast period.
The growth of the global market of oral anticoagulant is determined by several factors including the increase in the generality of the venous thromboembolism (VTE) and other cardiovascular disorders, The demand of the novel oral anticoagulants (NOACs), and the arises apprehension of novel oral anticoagulants the developing countries are the major factor for the growth of the market. The support for the growth of the market also comes from the increase in the number of elderly people and above, demand for novel therapeutics, and elevated unmet needs. The shortage of antidotes for NOACs and the higher or expensive prices of NOACs hampers the market growth during the forecast period. The value of the global anticoagulants market in 2017 at $24.265 million and is anticipated to reach $43,427 million by the end of 2025 with a growing CARG of 7.5% from 2018 to 2025
This report contains all the information on the global oral anticoagulants and the strength of the oral anticoagulant in the market. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other important factors. A detailed analysis of the oral anticoagulant globally and forecast to 2023 is also included in the report.
Covid 19 Analysis
The demand for the oral anticoagulant has increased due to the covid 19 pandemic. Though the market is facing some challenges due to the outbreak of the pandemic. Variation in the organic traffics and the response of the industries to the covid 19 cases has distinguished the market by generating alternatives. The report provides an analysis of the anticoagulants and injectable which are available in the market.
The most common type of anticoagulant in the market is warfarin, however, the emergence or the availability of new alternatives or new types of anticoagulants in the market is increasing commonly. The oral anticoagulants market size gets hampered due to the increases in the demand for the other alternatives.
The rise in the geriatric population, the increment in cardiovascular diseases, and the increase in the demand for surgical procedures are supporting the growth of the oral anticoagulant market shares during the forecast period.
On the basis of the reports from the Center For Diseases Control and Prevention, there are nearly 46.5 million procedures of surgeries are performed in the United States, every year. And according to the researches or reports from European Heart Network, 85 million population of in the European countries are living with cardiovascular disorders and according to the population prospects, the cases of aged people of 60 years or more are anticipated to double by the end of 2050.
The global anticoagulant market is estimated to reach USD 22,561.24 million by the end of 2023 with a 12.50% CAGR during the review period of 2018 to 2023, the largest shares in the market holding a value of USD 49 in 2017 according to the atrial fibrillation (AF)/ stroke prevention segment.
The data comprises the competitive scenarios of the global oral anticoagulant and it includes the economical and technical environment and the high growth regions and their political. These factors are linked with the growth of the market.
The estimates of the market have been considered after studying the various impact that includes social, economical, and political factors. The dynamics of the market are affecting the global anticoagulant market growth. The dynamic of the market includes porter’s five forces analysis that namely, bargaining power. The threat of new entrants, suppliers’ bargaining power, completion in the oral anticoagulant market globally, and the treats of the substitute.
The development of a novel oral anticoagulant market (NOACs) has increased the global anticoagulant market. The market is facing some challenges among which the side effects related to the drugs are the major cause. Stringent regulations from regulatory bodies and the high cost of oral anticoagulants are some other factors affecting the market growth.
According to the study, the anticoagulant growth momentum includes the increased incidence of cardiovascular diseases, the increase in the elderly population, and the newly listed drugs which are the improved versions of the existing drugs. On the basis of the evaluated pharmacy report, the highest annual growth rate of the top 15 treatment areas is due to the increased uses of Bayer’s Xarelto(rivaroxaban) and ringer’s Pradaxa (Clopidogrel) and clesulenol (enoxaparin). The two most favorable drugs in the anticoagulants are direct coagulation factor lla inhibitos which is representing the drug: Dabigatran etexilate and inhibitors of direct coagulation factor Xa which represents drugs: rivaroxaban, apixaban, etaneraban. FDA has approved three new oral anticoagulant drugs which are in use for the past few years. Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban) are considered as the major advance in thromboprophylaxis and in the field of anticoagulant therapy.
Value Chain Analysis
The global oral anticoagulant market is segmented into three types which include the indication of the diseases, channels of distribution, and regions. On the basis of the product, the market has been segmented into novel oral anticoagulants and warfarin. Acdeepcording to the indication of the diseases the market is segmented intodeep vein thrombosis/ pulmonary embolism, atrial fibrillation (AF)/ stroke prevention, and others. Based on the channels of distribution the global market is segmented into retail pharmacies, hospital pharmacies, and e-commerce.
The oral anticoagulant market is segmented into three types. On the basis of the indication of the diseases, the thinning medication market is segmented into pulmonary embolism (PE), heart attacks, artificial fibrillation (AF), and others. On the basis of the end-user segments the market, the segmented into retail pharmacy, online pharmacy, hospital pharmacy, and others.
A précising anticoagulant market shares come under the pulmonary embolism (PE) segment, as it is the most economically successful anticoagulant. The pulmonary embolism occurs in the pulmonary arteries of the lungs and it hunks the flow of the blood, this condition is very serious of life-threatening which ultimately triggers other serious health diseases.
The other contributing factors which are associated with pulmonary embolisms such as cancer obesity and heart attack are expected to drive the growth of the market.
The retail pharmacy segments are expected to hold the largest number of shares after the hospital pharmacy. The increased cases of re-filling the prescriptions and the efficient facilities proved by the institutes are the major factors driving the growth of the market.
On the basis of the regions, the global oral anticoagulant market is divided into the Americas, Europe, Asia-pacific, and the Middle East and Africa. The global anticoagulant market is expected to influence by the Americas. The increasing rates of cardiovascular disorders and the growth of surgical procedures. The European countries have shown a tremendous amount of growth due to the rising geriatric population in the market. It is estimated that Asia-pacific is the fastest-growing region of the market and the factor contributing to the growth of the market here are the rising populations and increased rates of cardiovascular diseases. The Middle East and Africa hold the least amount of shares as compared to the other regions.
The key strategies followed by the key player’s handling in the oral anticoagulant market shares were acquisition, launch, and expansion. Daiichi Sankyo Company Ltd launched oral anticoagulant Lixiana OD Tablets of dosages 15 mg, 30 mg, and 60 mg in 2017. Portola Pharmaceuticals Inc. received FDA approved Betrixaban for the prophylaxis of Venous Thromboembolism (VTE) in adult patients in the 2017and year 2016 Medicure received approval from the US FDA for its new "bolus vial" product.
The major key players of the global oral anticoagulant market are as follows.
The following report comprises of –
This report is to point out the high points of the oral anticoagulant markets in terms of the revenue hike by end of the global forecast year 2023.
Global Oral Anticoagulants Market, by Product
Global Oral Anticoagulants Market, by Disease Indication
Global Oral Anticoagulants Market, by Distribution Channel
Global Oral Anticoagulants Market, by Region
Frequently Asked Questions (FAQ) :
The global oral anticoagulants market is expected to reach a valuation of USD 22.5 billion by 2023.
The global oral coagulants market is expected to exhibit a strong 12.5% CAGR over the forecast period from 2020 to 2027.
The increasing prevalence of cardiovascular disorders is the major driver for the oral anticoagulants market.
The Americas is expected to dominate the global oral anticoagulants market.
Leading players in the oral anticoagulants market include Eli Lilly, AstraZeneca, GSK, Daiichi Sankyo, and Medicure, among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.